More Bad News for Rosiglitazone
For more than 10 years, thiazolidinediones (TZDs) have been prescribed for diabetes therapy in the U.S. on the sole basis of evidence that they improve glycemic control. An association of TZDs with heart failure is relatively well-established; however, recent data have implicated rosiglitazone in other adverse cardiovascular events as well.
Continua a leggere